New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis
Diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) is presently based on mainly clinical symptoms. BPS/IC can be considered as a worst-case scenario of bladder overactivity of unknown origin, including bladder pain. Usually, patients are partially or completely resistant to anticholin...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2011/639479 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563576957566976 |
|---|---|
| author | Jochen Neuhaus Thilo Schwalenberg Lars-Christian Horn Henry Alexander Jens-Uwe Stolzenburg |
| author_facet | Jochen Neuhaus Thilo Schwalenberg Lars-Christian Horn Henry Alexander Jens-Uwe Stolzenburg |
| author_sort | Jochen Neuhaus |
| collection | DOAJ |
| description | Diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) is presently based on mainly clinical symptoms. BPS/IC can be considered as a worst-case scenario of bladder overactivity of unknown origin, including bladder pain. Usually, patients are partially or completely resistant to anticholinergic therapy, and therapeutical options are especially restricted in case of BPS/IC. Therefore, early detection of patients prone to develop BPS/IC symptoms is essential for successful therapy. We propose extended diagnostics including molecular markers. Differential diagnosis should be based on three diagnostical “columns”: (i) clinical diagnostics, (ii) histopathology, and (iii) molecular diagnostics. Analysis of molecular alterations of receptor expression in detrusor smooth muscle cells and urothelial integrity is necessary to develop patient-tailored therapeutical concepts. Although more research is needed to elucidate the pathomechanisms involved, extended BPS/IC diagnostics could already be integrated into routine patient care, allowing evidence-based pharmacotherapy of patients with idiopathic bladder overactivity and BPS/IC. |
| format | Article |
| id | doaj-art-8acb33f1df1148afa850f753334ee040 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-8acb33f1df1148afa850f753334ee0402025-02-03T01:13:12ZengWileyAdvances in Urology1687-63691687-63772011-01-01201110.1155/2011/639479639479New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial CystitisJochen Neuhaus0Thilo Schwalenberg1Lars-Christian Horn2Henry Alexander3Jens-Uwe Stolzenburg4Department of Urology, University Hospital Leipzig, 04103 Leipzig, GermanyDepartment of Urology, University Hospital Leipzig, 04103 Leipzig, GermanyDepartment of Pathology, University of Leipzig, 04103 Leipzig, GermanyDepartment of Gynecology and Reproduction, University Hospital Leipzig, 04103 Leipzig, GermanyDepartment of Urology, University Hospital Leipzig, 04103 Leipzig, GermanyDiagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) is presently based on mainly clinical symptoms. BPS/IC can be considered as a worst-case scenario of bladder overactivity of unknown origin, including bladder pain. Usually, patients are partially or completely resistant to anticholinergic therapy, and therapeutical options are especially restricted in case of BPS/IC. Therefore, early detection of patients prone to develop BPS/IC symptoms is essential for successful therapy. We propose extended diagnostics including molecular markers. Differential diagnosis should be based on three diagnostical “columns”: (i) clinical diagnostics, (ii) histopathology, and (iii) molecular diagnostics. Analysis of molecular alterations of receptor expression in detrusor smooth muscle cells and urothelial integrity is necessary to develop patient-tailored therapeutical concepts. Although more research is needed to elucidate the pathomechanisms involved, extended BPS/IC diagnostics could already be integrated into routine patient care, allowing evidence-based pharmacotherapy of patients with idiopathic bladder overactivity and BPS/IC.http://dx.doi.org/10.1155/2011/639479 |
| spellingShingle | Jochen Neuhaus Thilo Schwalenberg Lars-Christian Horn Henry Alexander Jens-Uwe Stolzenburg New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis Advances in Urology |
| title | New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis |
| title_full | New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis |
| title_fullStr | New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis |
| title_full_unstemmed | New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis |
| title_short | New Aspects in the Differential Diagnosis and Therapy of Bladder Pain Syndrome/Interstitial Cystitis |
| title_sort | new aspects in the differential diagnosis and therapy of bladder pain syndrome interstitial cystitis |
| url | http://dx.doi.org/10.1155/2011/639479 |
| work_keys_str_mv | AT jochenneuhaus newaspectsinthedifferentialdiagnosisandtherapyofbladderpainsyndromeinterstitialcystitis AT thiloschwalenberg newaspectsinthedifferentialdiagnosisandtherapyofbladderpainsyndromeinterstitialcystitis AT larschristianhorn newaspectsinthedifferentialdiagnosisandtherapyofbladderpainsyndromeinterstitialcystitis AT henryalexander newaspectsinthedifferentialdiagnosisandtherapyofbladderpainsyndromeinterstitialcystitis AT jensuwestolzenburg newaspectsinthedifferentialdiagnosisandtherapyofbladderpainsyndromeinterstitialcystitis |